Compare WWR & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WWR | CPIX |
|---|---|---|
| Founded | 1977 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.3M | 73.6M |
| IPO Year | 2006 | 2007 |
| Metric | WWR | CPIX |
|---|---|---|
| Price | $0.55 | $5.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.92 | N/A |
| AVG Volume (30 Days) | ★ 950.0K | 178.2K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $42,010,949.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.75 |
| 52 Week Low | $0.46 | $1.85 |
| 52 Week High | $3.75 | $6.61 |
| Indicator | WWR | CPIX |
|---|---|---|
| Relative Strength Index (RSI) | 34.37 | 73.25 |
| Support Level | $0.56 | $2.81 |
| Resistance Level | $0.72 | $6.04 |
| Average True Range (ATR) | 0.03 | 0.41 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 10.12 | 69.64 |
Westwater Resources Inc is an energy technology company focused on developing battery-grade natural graphite materials through a vertically integrated, mine-to-market strategy anchored by its two primary projects in Coosa County, Alabama: the Kellyton Graphite Plant and the Coosa Graphite Deposit. Westwater also holds mineral rights to explore and mine the Coosa Graphite Deposit, which Westwater anticipates will eventually provide natural graphite flake concentrate as feedstock to the Kellyton Graphite Plant.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.